Literature DB >> 34207408

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Romain Eychenne1,2, Michel Chérel2, Férid Haddad1,3, François Guérard2, Jean-François Gestin2.   

Abstract

Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior, allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.

Entities:  

Keywords:  actinium-225; astatine-211; bismuth-212; bismuth-213; lead-212; radium-223; targeted alpha therapy; terbium-149; thorium-227; α-emitters

Year:  2021        PMID: 34207408      PMCID: PMC8234975          DOI: 10.3390/pharmaceutics13060906

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  265 in total

Review 1.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

2.  Solution thermodynamic stability of complexes formed with the octadentate hydroxypyridinonate ligand 3,4,3-LI(1,2-HOPO): a critical feature for efficient chelation of lanthanide(IV) and actinide(IV) ions.

Authors:  Gauthier J-P Deblonde; Manuel Sturzbecher-Hoehne; Rebecca J Abergel
Journal:  Inorg Chem       Date:  2013-07-16       Impact factor: 5.165

3.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Authors:  Matthias Miederer; Michael R McDevitt; George Sgouros; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

4.  Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.

Authors:  Nasir Abbas; Helen Heyerdahl; Øyvind S Bruland; Ellen Mengshoel Brevik; Jostein Dahle
Journal:  Curr Radiopharm       Date:  2013-06-06

5.  Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.

Authors:  Alexander H Staudacher; Eva Bezak; Artem Borysenko; Michael P Brown
Journal:  Nucl Med Commun       Date:  2014-12       Impact factor: 1.690

6.  Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics.

Authors:  Cristina Müller; Christiaan Vermeulen; Ulli Köster; Karl Johnston; Andreas Türler; Roger Schibli; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2016-03-28

7.  Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.

Authors:  Cristina Müller; Christoph A Umbricht; Nadezda Gracheva; Viviane J Tschan; Giovanni Pellegrini; Peter Bernhardt; Jan Rijn Zeevaart; Ulli Köster; Roger Schibli; Nicholas P van der Meulen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-27       Impact factor: 9.236

8.  Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.

Authors:  Darpan N Pandya; Roy Hantgan; Mikalai M Budzevich; Nancy D Kock; David L Morse; Izadora Batista; Akiva Mintz; King C Li; Thaddeus J Wadas
Journal:  Theranostics       Date:  2016-03-01       Impact factor: 11.556

9.  Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.

Authors:  Marisa Capitao; Justine Perrin; Sylvain Simon; Sébastien Gouard; Nicolas Chouin; Frank Bruchertseifer; Alfred Morgenstern; Latifa Rbah-Vidal; Michel Chérel; Emmanuel Scotet; Nathalie Labarrière; Yannick Guilloux; Joëlle Gaschet
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

View more
  9 in total

1.  Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.

Authors:  Vandana Batra; Minu Samanta; Mehran Makvandi; David Groff; Paul Martorano; Jimmy Elias; Pietro Ranieri; Matthew Tsang; Catherine Hou; Yimei Li; Bruce Pawel; Daniel Martinez; Ganesan Vaidyanathan; Sean Carlin; Daniel A Pryma; John M Maris
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

Review 2.  Compton imaging for medical applications.

Authors:  Hideaki Tashima; Taiga Yamaya
Journal:  Radiol Phys Technol       Date:  2022-07-22

3.  Where do we stand with radioimmunotherapy for acute myeloid leukemia?

Authors:  Roland B Walter
Journal:  Expert Opin Biol Ther       Date:  2022-03-31       Impact factor: 5.589

4.  Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa.

Authors:  Aohan Hu; Victoria Brown; Samantha N MacMillan; Valery Radchenko; Hua Yang; Luke Wharton; Caterina F Ramogida; Justin J Wilson
Journal:  Inorg Chem       Date:  2021-12-29       Impact factor: 5.436

5.  Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001.

Authors:  Vilde Yuli Stenberg; Anna Julie Kjøl Tornes; Hogne Røed Nilsen; Mona-Elisabeth Revheim; Øyvind Sverre Bruland; Roy Hartvig Larsen; Asta Juzeniene
Journal:  Cancers (Basel)       Date:  2022-06-03       Impact factor: 6.575

Review 6.  Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.

Authors:  Xu Zhou; Linlin Dong; Langtao Shen
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

Review 7.  Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

Authors:  Maria I Del Olmo-García; Stefan Prado-Wohlwend; Pilar Bello; Angel Segura; Juan F Merino-Torres
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

Review 8.  Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.

Authors:  Maria Isabel Del Olmo-Garcia; Stefan Prado-Wohlwend; Alexia Andres; Jose M Soriano; Pilar Bello; Juan Francisco Merino-Torres
Journal:  Biomedicines       Date:  2021-12-01

Review 9.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.